Analyst Report - PAC Partners (4 December 2017)
Analyst report from PAC Partners evaluating how LBT Innovations is using artificial intelligence to improve pathology bottlenecks.
- Every day 50,000 hand sized agar plates are analysed by highly trained staff, and more than 80% are negative.
- The gold standard for culling negatives automatically still requires human analysis intervention and costs US$3.0m.
- LBT’s solution is just US$0.3m and is only USFDA approved Artificial Intelligent plate reader. It allows trained professionals to focus on the ~20% of positive plates.
- We estimate LBT will sell at least five units to reference sites within 12 months, and 50 in FY20 for $3m EBITDA.
- LBT could be cash positive in FY’18F, however it will use primary screening introduction for other development.
PLEASE DOWNLOADED THE ATTACHED DETAILED REPORT
- 7 Dec 2017 -- $2.5M Grant Awarded to Advance WoundVue Development
- 4 Dec 2017 -- Appendix 3B
- 1 Dec 2017 -- Appendix 3B
Company OverviewOver the past decade, LBT Innovations has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefi...
MicroStreakIn its first five years of global sales, LBT’s MicroStreak technology captured the largest share of the international market for automated culture-plate streaking and inoculation. Originally sold by bi...
APASThe Automated Plate Assessment System, or APAS, is a platform technology for the automation of culture-plate screening and interpretation. While LBT’s first product, PREVI Isola, automates the inoculati...